XYOTAX PATENT ALLOWANCE PROVIDES EXCLUSIVITY IN JAPAN UNTIL 2018

Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced that it has received notification from the Japanese Patent Office that patent coverage extending to XYOTAX(TM) (paclitaxel poliglumex) is allowable in Japan. CTI has an exclusive license to this Japanese patent property. The patent, when issued, will provide patent protection for XYOTAX in Japan until 2018. In addition to this licensed patent property in Japan, CTI has licensed issued patents in the United States and allowed coverage in Europe that encompass XYOTAX.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/01c818c6c9c111e0c3ef4282b6920a5c.html)